Skip to main content
Top
Published in: Critical Care 1/2013

Open Access 01-02-2013 | Research

Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate

Authors: Rile Ge, Ervin Pejo, Joseph F Cotten, Douglas E Raines

Published in: Critical Care | Issue 1/2013

Login to get access

Abstract

Introduction

Etomidate is no longer administered as a continuous infusion for anesthetic maintenance or sedation, because it results in profound and persistent suppression of adrenocortical steroid synthesis with potentially lethal consequences in critically ill patients. We hypothesized that rapidly metabolized soft analogues of etomidate could be developed that do not produce persistent adrenocortical dysfunction even after prolonged continuous infusion. We hope that such agents might also provide more rapid and predictable anesthetic emergence. We have developed the soft etomidate analogue cyclopropyl-methoxycarbonyl etomidate (CPMM). Upon termination of 120-minute continuous infusions, hypnotic and encephalographic recoveries occur in four minutes. The aims of this study were to assess adrenocortical function during and following 120-minute continuous infusion of CPMM and to compare the results with those obtained using etomidate.

Methods

Dexamethasone-suppressed rats were randomized into an etomidate group, CPMM group, or control group. Rats in the etomidate and CPMM groups received 120-minute continuous infusions of etomidate and CPMM, respectively. Rats in the control group received neither hypnotic. In the first study, adrenocortical function during hypnotic infusion was assessed by administering adrenocorticotropic hormone (ACTH) 90 minutes after the start of the hypnotic infusion and measuring plasma corticosterone concentrations at the end of the infusion 30 minutes later. In the second study, adrenocortical recovery following hypnotic infusion was assessed by administering ACTH every 30 minutes after infusion termination and measuring plasma corticosterone concentrations 30 minutes after each ACTH dose.

Results

During hypnotic infusion, ACTH-stimulated serum corticosterone concentrations were significantly lower in the CPMM and etomidate groups than in the control group (100 ± 64 ng/ml and 33 ± 32 ng/ml versus 615 ± 265 ng/ml, respectively). After hypnotic infusion, ACTH-stimulated serum corticosterone concentrations recovered to control values within 30 minutes in the CPMM group but remained suppressed relative to those in the control group for more than 3 hours in the etomidate group.

Conclusions

Both CPMM and etomidate suppress adrenocortical function during continuous infusion. However, recovery occurs significantly more rapidly following infusion of CPMM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Godefroi EF, Janssen PA, Vandereycken CA, Vanheertum AH, Niemegeers CJ: Dl-1-(1-arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agent. J Med Chem 1965, 8: 220-223. 10.1021/jm00326a017CrossRefPubMed Godefroi EF, Janssen PA, Vandereycken CA, Vanheertum AH, Niemegeers CJ: Dl-1-(1-arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agent. J Med Chem 1965, 8: 220-223. 10.1021/jm00326a017CrossRefPubMed
2.
go back to reference Ledingham IM, Watt I: Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1: 1270.CrossRefPubMed Ledingham IM, Watt I: Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1: 1270.CrossRefPubMed
3.
go back to reference Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984, 39: 973-981. 10.1111/j.1365-2044.1984.tb08885.xCrossRefPubMed Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984, 39: 973-981. 10.1111/j.1365-2044.1984.tb08885.xCrossRefPubMed
4.
go back to reference Fry DE, Griffiths H: The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984, 20: 625-629. 10.1111/j.1365-2265.1984.tb00112.xCrossRef Fry DE, Griffiths H: The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984, 20: 625-629. 10.1111/j.1365-2265.1984.tb00112.xCrossRef
5.
go back to reference den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC: Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005, 90: 5110-5117. 10.1210/jc.2005-1107CrossRefPubMed den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC: Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005, 90: 5110-5117. 10.1210/jc.2005-1107CrossRefPubMed
6.
go back to reference Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, Bellissant E, Annane D: Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007, 35: 1012-1018. 10.1097/01.CCM.0000259465.92018.6ECrossRefPubMed Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, Bellissant E, Annane D: Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007, 35: 1012-1018. 10.1097/01.CCM.0000259465.92018.6ECrossRefPubMed
7.
go back to reference Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE: Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008, 65: 573-579. 10.1097/TA.0b013e31818255e8CrossRefPubMed Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE: Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008, 65: 573-579. 10.1097/TA.0b013e31818255e8CrossRefPubMed
8.
go back to reference Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG: The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35: 1868-1876. 10.1007/s00134-009-1603-4CrossRefPubMed Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG: The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35: 1868-1876. 10.1007/s00134-009-1603-4CrossRefPubMed
9.
go back to reference Chan CM, Mitchell AL, Shorr AF: Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012, 40: 2945-2953. 10.1097/CCM.0b013e31825fec26CrossRefPubMed Chan CM, Mitchell AL, Shorr AF: Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012, 40: 2945-2953. 10.1097/CCM.0b013e31825fec26CrossRefPubMed
10.
go back to reference Asehnoune K, Mahe PJ, Seguin P, Jaber S, Jung B, Guitton C, Chatel-Josse N, Subileau A, Tellier AC, Masson F, Renard B, Malledant Y, Lejus C, Volteau C, Sebille V, Roquilly A: Etomidate increases susceptibility to pneumonia in trauma patients. Intensive Care Med 2012, 38: 1673-1682. 10.1007/s00134-012-2619-8CrossRefPubMed Asehnoune K, Mahe PJ, Seguin P, Jaber S, Jung B, Guitton C, Chatel-Josse N, Subileau A, Tellier AC, Masson F, Renard B, Malledant Y, Lejus C, Volteau C, Sebille V, Roquilly A: Etomidate increases susceptibility to pneumonia in trauma patients. Intensive Care Med 2012, 38: 1673-1682. 10.1007/s00134-012-2619-8CrossRefPubMed
11.
go back to reference Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE: Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009, 111: 240-249. 10.1097/ALN.0b013e3181ae63d1PubMedCentralCrossRefPubMed Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE: Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009, 111: 240-249. 10.1097/ALN.0b013e3181ae63d1PubMedCentralCrossRefPubMed
12.
go back to reference Ge RL, Pejo E, Haburcak M, Husain SS, Forman SA, Raines DE: Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite. Anesth Analg 2012, 115: 305-308. 10.1213/ANE.0b013e318239c6caPubMedCentralCrossRefPubMed Ge RL, Pejo E, Haburcak M, Husain SS, Forman SA, Raines DE: Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite. Anesth Analg 2012, 115: 305-308. 10.1213/ANE.0b013e318239c6caPubMedCentralCrossRefPubMed
13.
go back to reference Pejo E, Ge R, Banacos N, Cotten JF, Husain SS, Raines DE: Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite following continuous infusions of a rapidly metabolized eomidate analog in rats. Anesthesiology 2012, 116: 1057-1065. 10.1097/ALN.0b013e3182515403PubMedCentralCrossRefPubMed Pejo E, Ge R, Banacos N, Cotten JF, Husain SS, Raines DE: Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite following continuous infusions of a rapidly metabolized eomidate analog in rats. Anesthesiology 2012, 116: 1057-1065. 10.1097/ALN.0b013e3182515403PubMedCentralCrossRefPubMed
14.
go back to reference Husain SS, Pejo E, Ge R, Raines DE: Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology 2012, 117: 1027-1036. 10.1097/ALN.0b013e31826d3befPubMedCentralCrossRefPubMed Husain SS, Pejo E, Ge R, Raines DE: Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology 2012, 117: 1027-1036. 10.1097/ALN.0b013e31826d3befPubMedCentralCrossRefPubMed
15.
go back to reference Ge R, Pejo E, Husain SS, Cotten JF, Raines DE: Electroencephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology 2012, 117: 1037-1043. 10.1097/ALN.0b013e31826d3de2PubMedCentralCrossRefPubMed Ge R, Pejo E, Husain SS, Cotten JF, Raines DE: Electroencephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology 2012, 117: 1037-1043. 10.1097/ALN.0b013e31826d3de2PubMedCentralCrossRefPubMed
16.
go back to reference de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW: Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984, 59: 1143-1147. 10.1210/jcem-59-6-1143CrossRefPubMed de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW: Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984, 59: 1143-1147. 10.1210/jcem-59-6-1143CrossRefPubMed
17.
go back to reference Fragen RJ, Shanks CA, Molteni A, Avram MJ: Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984, 61: 652-656. 10.1097/00000542-198412000-00004CrossRefPubMed Fragen RJ, Shanks CA, Molteni A, Avram MJ: Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984, 61: 652-656. 10.1097/00000542-198412000-00004CrossRefPubMed
18.
go back to reference Wagner RL, White PF: Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984, 61: 647-651. 10.1097/00000542-198412000-00003CrossRefPubMed Wagner RL, White PF: Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984, 61: 647-651. 10.1097/00000542-198412000-00003CrossRefPubMed
19.
go back to reference Fellows IW, Bastow MD, Byrne AJ, Allison SP: Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983, 287: 1835-1837. 10.1136/bmj.287.6408.1835CrossRef Fellows IW, Bastow MD, Byrne AJ, Allison SP: Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983, 287: 1835-1837. 10.1136/bmj.287.6408.1835CrossRef
20.
go back to reference Absalom A, Pledger D, Kong A: Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999, 54: 861-867. 10.1046/j.1365-2044.1999.01003.xCrossRefPubMed Absalom A, Pledger D, Kong A: Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999, 54: 861-867. 10.1046/j.1365-2044.1999.01003.xCrossRefPubMed
21.
go back to reference den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF: One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008, 34: 163-168. 10.1007/s00134-007-0836-3PubMedCentralCrossRefPubMed den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF: One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008, 34: 163-168. 10.1007/s00134-007-0836-3PubMedCentralCrossRefPubMed
22.
go back to reference Kulstad EB, Kalimullah EA, Tekwani KL, Courtney DM: Etomidate as an induction agent in septic patients: red flags or false alarms? West J Emerg Med 2010, 11: 161-172.PubMedCentralPubMed Kulstad EB, Kalimullah EA, Tekwani KL, Courtney DM: Etomidate as an induction agent in septic patients: red flags or false alarms? West J Emerg Med 2010, 11: 161-172.PubMedCentralPubMed
23.
go back to reference Tomlin SL, Jenkins A, Lieb WR, Franks NP: Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals. Anesthesiology 1998, 88: 708-717. 10.1097/00000542-199803000-00022CrossRefPubMed Tomlin SL, Jenkins A, Lieb WR, Franks NP: Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals. Anesthesiology 1998, 88: 708-717. 10.1097/00000542-199803000-00022CrossRefPubMed
24.
go back to reference Husain SS, Ziebell MR, Ruesch D, Hong F, Arevalo E, Kosterlitz JA, Olsen RW, Forman SA, Cohen JB, Miller KW: 2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem 2003, 46: 1257-1265. 10.1021/jm020465vCrossRefPubMed Husain SS, Ziebell MR, Ruesch D, Hong F, Arevalo E, Kosterlitz JA, Olsen RW, Forman SA, Cohen JB, Miller KW: 2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem 2003, 46: 1257-1265. 10.1021/jm020465vCrossRefPubMed
25.
go back to reference Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits JF, Beugels I, Emmen J, Ottenheijm HCJ, Leysen D, Hermans JJR: Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007, 21: 455-471. 10.1007/s10822-007-9128-9PubMedCentralCrossRefPubMed Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits JF, Beugels I, Emmen J, Ottenheijm HCJ, Leysen D, Hermans JJR: Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007, 21: 455-471. 10.1007/s10822-007-9128-9PubMedCentralCrossRefPubMed
26.
go back to reference Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW, Stewart D, Liu A, Raines DE: Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112: 637-644. 10.1097/ALN.0b013e3181cf40edPubMedCentralCrossRefPubMed Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW, Stewart D, Liu A, Raines DE: Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112: 637-644. 10.1097/ALN.0b013e3181cf40edPubMedCentralCrossRefPubMed
28.
go back to reference Calvo R, Carlos R, Erill S: Etomidate and plasma esterase activity in man and experimental animals. Pharmacology 1979, 18: 294-298. 10.1159/000137268CrossRefPubMed Calvo R, Carlos R, Erill S: Etomidate and plasma esterase activity in man and experimental animals. Pharmacology 1979, 18: 294-298. 10.1159/000137268CrossRefPubMed
29.
go back to reference Quon CY, Mai K, Patil G: Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988, 16: 425-428.PubMed Quon CY, Mai K, Patil G: Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988, 16: 425-428.PubMed
30.
go back to reference Egan TD: Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 2009, 111: 229-230. 10.1097/ALN.0b013e3181ae8460CrossRefPubMed Egan TD: Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 2009, 111: 229-230. 10.1097/ALN.0b013e3181ae8460CrossRefPubMed
31.
go back to reference Bodor N, Buchwald P: Soft drug design: general principles and recent applications. Med Res Rev 2000, 20: 58-101. 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-XCrossRefPubMed Bodor N, Buchwald P: Soft drug design: general principles and recent applications. Med Res Rev 2000, 20: 58-101. 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-XCrossRefPubMed
32.
go back to reference Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V: Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs 2012, 21: 1089-1106. 10.1517/13543784.2012.693477CrossRefPubMed Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V: Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs 2012, 21: 1089-1106. 10.1517/13543784.2012.693477CrossRefPubMed
33.
go back to reference Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM: A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012, 115: 274-283. 10.1213/ANE.0b013e31823f0c28CrossRefPubMed Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM: A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012, 115: 274-283. 10.1213/ANE.0b013e31823f0c28CrossRefPubMed
Metadata
Title
Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate
Authors
Rile Ge
Ervin Pejo
Joseph F Cotten
Douglas E Raines
Publication date
01-02-2013
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2013
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc12494

Other articles of this Issue 1/2013

Critical Care 1/2013 Go to the issue